Biostage, Inc. Changes Name to Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN)PRNewsWire • 07/20/23
Biostage Activated Mayo Clinic as The First Site for Clinical Trial in Severe Esophageal DiseasePRNewsWire • 07/18/23
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Biostage, Inc. for Potential Breaches of Fiduciary Duty By Its Board of DirectorsPRNewsWire • 06/15/23
Biostage Initiated Study Start-up Activities for Clinical Trial in Severe Esophageal DiseaseGlobeNewsWire • 05/31/23
Biostage Selects IQVIA to Manage its FDA-Approved Clinical Trial in Severe Esophageal Disease, including CancerPRNewsWire • 12/28/22
New Publication Demonstrates Rapid Esophageal Regeneration using the Biostage Esophageal ImplantPRNewsWire • 12/23/22
Biostage Receives U.S. Patent for Cellularized Patch-Based Scaffolds for Organ RepairPRNewsWire • 10/25/22
Biostage Announces Publication of Mechanical Strength Data for Regenerated Esophageal Tissue in Journal of BiomechanicsPRNewsWire • 06/15/22
Biostage, Inc. (BSTG) Interim CEO David Green on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/17/22
Biostage Further Strengthens IP Portfolio with Additional Patent for Regeneration and Repair of the BronchusPRNewsWire • 04/11/22